Sperimentazioni cliniche
Early University of Calgary trial tests high-dose niacin as add-on treatment for glioblastoma
Riportato dall'IA Immagine generata dall'IA Verificato
Researchers at the University of Calgary are studying whether high doses of vitamin B3 (niacin) can improve outcomes for patients with newly diagnosed glioblastoma when added to standard treatment. An interim analysis of 24 patients found a higher-than-expected six‑month progression‑free survival rate, though investigators stress the results are preliminary and require ongoing safety monitoring.
A new experimental oral medication called elecoglipron improved blood sugar control and promoted weight loss in adults with type 2 diabetes during a phase 2b trial. Results from the SOLSTICE study were presented at the American Diabetes Association's Scientific Sessions and published in The Lancet.
Riportato dall'IA
A new treatment called Daraxonrasib has shown strong results against advanced pancreatic cancer in a recent clinical trial. The drug targets a genetic mutation long considered impossible to treat effectively.
Takeda Pharmaceutical has announced that its AI-assisted oral psoriasis drug zasocitinib proved safe and effective in late-stage trials. The once-daily pill outperformed placebo and the existing therapy apremilast in clearing skin for patients with moderate-to-severe plaque psoriasis. If approved, it would mark one of the first drugs discovered with artificial intelligence.
Riportato dall'IA
Un vaccino nasale sperimentale ha per la prima volta impedito la colonizzazione del batterio della pertosse negli umani, secondo un trial clinico recentemente pubblicato. Questa svolta potrebbe frenare la diffusione della malattia, in particolare in un anno di casi record in Inghilterra. Il vaccino BPZE1, sviluppato da ILiAD Biotechnologies, ha ridotto la presenza batterica di oltre il 97% rispetto al placebo.
A combination of enzalutamide and hormone therapy has reduced the risk of death by more than 40% in men with recurring prostate cancer, according to a major clinical trial. The study, involving over 1,000 patients worldwide, was led by researchers at Cedars-Sinai and presented at a medical congress in Berlin. Experts describe the findings as a game changer for treating aggressive cases.
Riportato dall'IA
The U.S. Food and Drug Administration has finalized a rule requiring drug sponsors to submit diversity action plans for clinical trials. This aims to ensure better representation of underrepresented groups in medical research. The rule takes effect in 2025.
Virus injection halts pancreatic tumor growth in trial
28 maggio 2026 16:21Gene-editing drug slashes bad cholesterol 62 percent in trial
25 maggio 2026 16:39Study finds beta blockers offer no benefit after uncomplicated heart attacks
17 maggio 2026 08:37Tenaya Therapeutics publishes RIDGE-1 data on TN-401 gene therapy
12 maggio 2026 11:26Intellia reports strong phase iii results for hae treatment
22 novembre 2025 02:26Stem cell therapy restores vision in AMD patients
13 novembre 2025 04:09Cheap gout drug colchicine may prevent heart attacks and strokes
06 novembre 2025 13:09Oral semaglutide pill yields up to 16.6% weight loss in NEJM obesity trial
22 ottobre 2025 20:00Wegovy provides heart benefits even with minimal weight loss
20 ottobre 2025 00:10New compounds halt cancer growth without damaging healthy cells